NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

EXOZ

eXoZymes Inc

Jul 11 • 04:00PM ET

9.81

Dollar change -0.21
Percentage change -2.10	%

Healthcare • Biotechnology • USA • NASD

Held by: VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	77.38%	Shs Outstand	8.37M	Perf Week	-1.01%
Market Cap	82.11M	Forward P/E	-	EPS next Y	-	Insider Trans	0.05%	Shs Float	1.89M	Perf Month	-26.98%
Enterprise Value	74.93M	PEG	-	EPS next Q	-	Inst Own	0.92%	Short Float	0.90%	Perf Quarter	-6.03%
Income	-	P/S	-	EPS this Y	-	Inst Trans	-0.53%	Short Ratio	1.53	Perf Half Y	-38.88%
Sales	-	P/B	9.24	EPS next Y	-	ROA	-	Short Interest	0.02M	Perf YTD	-40.55%
Book/sh	1.06	P/C	9.65	EPS next 5Y	-	ROE	-	52W High	23.99 -59.11%	Perf Year	-
Cash/sh	1.02	P/FCF	-	EPS past 3/5Y	-145.11% -	ROIC	-	52W Low	8.50 15.41%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	2.13% 7.14%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	0.78	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.52	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	38.46	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	6.52	EPS Q/Q	-	SMA20	-8.15%	Beta	-	Target Price	-
Payout	-	Debt/Eq	0.15	Sales Q/Q	-	SMA50	-19.42%	Rel Volume	0.05	Prev Close	10.02
Employees	31	LT Debt/Eq	0.12	Earnings	May 12 AMC	SMA200	-27.96%	Avg Volume	11.14K	Price	9.81
IPO	Nov 13, 2024	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	601	Change	-2.10%

Jun-26-25 04:10PM	eXoZymes Selected as Core Industry Partner in $9M NSF-Funded Initiative to Advance Modular Cell-Free Biomanufacturing (ACCESSWIRE) -5.03% +6.83%
May-16-25 09:25AM	eXoZymes Highlights Scalable Biomanufacturing Platform and First Spinout, NCTx, on Grow Everything Podcast (ACCESSWIRE) +10.96%
May-12-25 04:10PM	eXoZymes Provides First Quarter 2025 and NCTx Subsidiary Update at 5PM EST Today (ACCESSWIRE) +16.03%
May-07-25 05:20PM	eXoZymes to Host First Quarter 2025 and Subsidiary NCTx Update on Monday May 12, 2025, at 5PM EST (ACCESSWIRE) +13.73%
May-06-25 04:10PM	eXoZymes Launches Subsidiary, NCTx, to Unlock a Promising Compound for Gut and Liver Health (ACCESSWIRE)
04:10PM	Loading…
Apr-21-25 04:10PM	Bringing clarity and precision to the cell-free space by introducing exozymes (GlobeNewswire) +12.61%
Apr-10-25 04:30PM	BioClick an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grant (GlobeNewswire) -7.39%
Apr-02-25 04:10PM	eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO (GlobeNewswire)
04:05PM	eXoZymes Provides Fourth Quarter and Full Year 2024 Update (GlobeNewswire)
Mar-26-25 05:00PM	eXoZymes to Host Fourth Quarter and Full Year 2024 Results Conference Call on Wednesday April 2, 2025 (GlobeNewswire) -19.67%
Mar-03-25 08:40PM	New to the Street Airs Show #630 on Fox Business Network Tonight at 10:30 PM PST Featuring Roadzen ($RDZN), BioVie ($BIVI), AtlasClear (ATCH), eXoZymes ($EXOZ), and EvolveHealthandLifestyle.com With Craig Bruce (ACCESS Newswire)
Feb-21-25 04:05PM	eXoZymes and MDB Capital Announce Leadership Transition at eXoZymes Inc. (GlobeNewswire)
Feb-19-25 08:25AM	eXoZymes Announces Nasdaq Bell Ringing to Commemorate Initial Public Offering (GlobeNewswire)
Feb-10-25 11:00AM	Invizyne Technologies Announces Name Change to eXoZymes, Inc. and New Ticker Symbol (GlobeNewswire)
Nov-19-24 09:05AM	Invizyne Technologies Selected for $2 Million Project to Advance Sustainable Aviation Fuel Capabilities (GlobeNewswire) +14.54%
04:05PM	Loading…
Nov-14-24 04:05PM	Invizyne Technologies Announces Closing of Initial Public Offering (GlobeNewswire) +19.77% +7.34%
Nov-13-24 04:05PM	Invizyne's Nasdaq IPO Marks New Era of Biomanufacturing (GlobeNewswire)
09:05AM	Invizyne Technologies Begins Trading on NASDAQ (GlobeNewswire)
Nov-12-24 10:52AM	Invizyne Technologies to Begin Trading on NASDAQ on November 13, 2024 (GlobeNewswire)

eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Heltzen Michael	Chief Executive Officer	Jul 02 '25	Buy	10.22	1,040	10,629	10,629	Jul 02 05:49 PM
Heltzen Michael	Chief Executive Officer	Jan 17 '25	Buy	10.78	1,767	19,048	3,872	Jan 21 06:02 AM
Heltzen Michael	Chief Executive Officer	Jan 16 '25	Buy	10.72	121	1,297	2,105	Jan 21 06:02 AM
Heltzen Michael	Chief Executive Officer	Nov 15 '24	Buy	11.10	1,984	22,022	1,984	Nov 19 06:45 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

EXOZ

eXoZymes Inc

Upgrade your FINVIZ experience